Pion screening mass at finite chemical potential

We present a method to compute the responses of meson screening masses to the chemical potential by Taylor expanding the correlator using lattice QCD simulation. We start by comparing the free theory lattice results with the analytical expression. Then, using symmetry arguments, we obtain an expression for the correlator in a series of the chemical potential at finite temperature. Using this, we obtain the lowest order correction to the screening mass at a finite chemical potential for temperatures around 2.5 GeV. Our lattice analysis is limited to isoscalar chemical potential for the pseudoscalar channel. The calculations were performed using (2+1)-flavors of the Highly Improved Staggered Quark (HISQ/tree) action, with the ratio of the strange quark mass to the light quark mass $m_s/m_\ell=20$ corresponding to pion masses of 160 MeV.Comment: 18 pages, 16 figure

On designing light-weight object trackers through network pruning: Use CNNs or transformers?

Object trackers deployed on low-power devices need to be light-weight, however, most of the current state-of-the-art (SOTA) methods rely on using compute-heavy backbones built using CNNs or transformers. Large sizes of such models do not allow their deployment in low-power conditions and designing compressed variants of large tracking models is of great importance. This paper demonstrates how highly compressed light-weight object trackers can be designed using neural architectural pruning of large CNN and transformer based trackers. Further, a comparative study on architectural choices best suited to design light-weight trackers is provided. A comparison between SOTA trackers using CNNs, transformers as well as the combination of the two is presented to study their stability at various compression ratios. Finally results for extreme pruning scenarios going as low as 1% in some cases are shown to study the limits of network pruning in object tracking. This work provides deeper insights into designing highly efficient trackers from existing SOTA methods.Comment: Submitted at IEEE ICASSP 202

Efficacy and toxicity of SBRT in advanced hepatocellular carcinoma with portal vein tumor thrombosis — a retrospective study

BACKGROUND: The purpose of this study was to evaluate the outcome of stereotactic body radiation therapy (SBRT) in patients of unresectable hepatocellular carcinoma (HCC) complicated with portal vein tumor thrombosis (PVTT) who are also unsuitable for other locoregional therapies. MATERIALS AND METHODS: Between May 2018 and January 2020, twenty-nine patients with advanced unresectable HCCs, treated with SBRT, were enrolled in this retrospective audit. Patients of Child status A5-B7 and with healthy liver volume, ≥ 700 ccs were treated. Local control (LC), overall survival (OS), progression-free survival (PFS), PVTT opening rate, and effect of prognostic factors were analyzed. RESULTS: The median tumor diameter was 8.6 cm (5–14), and the median tumor volume was 275 cc (151–1196). The median SBRT dose prescription was 48 Gy in 6 fractions (32–50 Gy in 5–6 fractions). The median follow up was eight months (1–20), 1-year local control, progression-free survival, and overall survival were 95%, 53.4%, and 60%, respectively. Overall rate of grade III toxicity was less than 5%, and the most common toxicity was lymphocytopenia. Tumors of more than 350cc had worse OS and PFS when compared to tumors < 350 cc (median OS and PFS of tumors > 350 cc was 4 months and two months, p = .01 and .003, respectively). A total of fifteen patients progressed with the disease and the median time to progression was two months [1–4]. CONCLUSION: SBRT is safe and provides excellent local control in advanced HCC complicated with PVTT. The out of field failure pattern and time to failure in these patients highlights the need for adjuvant systemic therapy after completion of local treatment. Our data warrant the need for multimodality trials in this patient cohort

A Case Study of a Pilot Smart Home Monitoring System with Older Adults Living Alone in East Midlands

open access articleThe aim of this project was to examine older adults and their next-of-kins’ experiences of using smart home technology. The technology unobtrusively monitors the older adult’s physical functional ability to undertake their daily activities at home. Using a case study approach, the participants comprised three family units: three older adults with a history of long-term co-morbidities and who lived alone, along with their next-of-kin (n=4). The older adults were all female aged between 72- 82 years of age, while the four next-of-kin were all females aged between 40 and 55 years of age. Participants experiences of using the smart home technology was evaluated at three- and eight-months post installation via in-depth one-to-one interviews with the older adults and their next-of-kin. The older adults described how the smart home sensors reduced their levels of anxiety because they were ‘not feeling alone’. Likewise, their next-of-kin described how the sensors gave them an insight to their older relatives’ activities of daily living, as well as the challenges they experienced. The findings highlighted the benefit of smart home technologies in terms of helping older adults and their next-of-kin monitor their daily activities, reduce social isolation, and adopt positive health and behavioural changes

The International Natural Product Sciences Taskforce (INPST) and the power of Twitter networking exemplified through #INPST hashtag analysis

Background: The development of digital technologies and the evolution of open innovation approaches have enabled the creation of diverse virtual organizations and enterprises coordinating their activities primarily online. The open innovation platform titled "International Natural Product Sciences Taskforce" (INPST) was established in 2018, to bring together in collaborative environment individuals and organizations interested in natural product scientific research, and to empower their interactions by using digital communication tools. Methods: In this work, we present a general overview of INPST activities and showcase the specific use of Twitter as a powerful networking tool that was used to host a one-week "2021 INPST Twitter Networking Event" (spanning from 31st May 2021 to 6th June 2021) based on the application of the Twitter hashtag #INPST. Results and Conclusion: The use of this hashtag during the networking event period was analyzed with Symplur Signals (https://www.symplur.com/), revealing a total of 6,036 tweets, shared by 686 users, which generated a total of 65,004,773 impressions (views of the respective tweets). This networking event's achieved high visibility and participation rate showcases a convincing example of how this social media platform can be used as a highly effective tool to host virtual Twitter-based international biomedical research events

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Background: The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to establish whether the addition of molnupiravir to usual care reduced hospital admissions and deaths associated with COVID-19 in this population. Methods: PANORAMIC was a UK-based, national, multicentre, open-label, multigroup, prospective, platform adaptive randomised controlled trial. Eligible participants were aged 50 years or older—or aged 18 years or older with relevant comorbidities—and had been unwell with confirmed COVID-19 for 5 days or fewer in the community. Participants were randomly assigned (1:1) to receive 800 mg molnupiravir twice daily for 5 days plus usual care or usual care only. A secure, web-based system (Spinnaker) was used for randomisation, which was stratified by age (<50 years vs ≥50 years) and vaccination status (yes vs no). COVID-19 outcomes were tracked via a self-completed online daily diary for 28 days after randomisation. The primary outcome was all-cause hospitalisation or death within 28 days of randomisation, which was analysed using Bayesian models in all eligible participants who were randomly assigned. This trial is registered with ISRCTN, number 30448031. Findings: Between Dec 8, 2021, and April 27, 2022, 26 411 participants were randomly assigned, 12 821 to molnupiravir plus usual care, 12 962 to usual care alone, and 628 to other treatment groups (which will be reported separately). 12 529 participants from the molnupiravir plus usual care group, and 12 525 from the usual care group were included in the primary analysis population. The mean age of the population was 56·6 years (SD 12·6), and 24 290 (94%) of 25 708 participants had had at least three doses of a SARS-CoV-2 vaccine. Hospitalisations or deaths were recorded in 105 (1%) of 12 529 participants in the molnupiravir plus usual care group versus 98 (1%) of 12 525 in the usual care group (adjusted odds ratio 1·06 [95% Bayesian credible interval 0·81–1·41]; probability of superiority 0·33). There was no evidence of treatment interaction between subgroups. Serious adverse events were recorded for 50 (0·4%) of 12 774 participants in the molnupiravir plus usual care group and for 45 (0·3%) of 12 934 in the usual care group. None of these events were judged to be related to molnupiravir. Interpretation: Molnupiravir did not reduce the frequency of COVID-19-associated hospitalisations or death among high-risk vaccinated adults in the community

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

BackgroundThe safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to establish whether the addition of molnupiravir to usual care reduced hospital admissions and deaths associated with COVID-19 in this population.MethodsPANORAMIC was a UK-based, national, multicentre, open-label, multigroup, prospective, platform adaptive randomised controlled trial. Eligible participants were aged 50 years or older—or aged 18 years or older with relevant comorbidities—and had been unwell with confirmed COVID-19 for 5 days or fewer in the community. Participants were randomly assigned (1:1) to receive 800 mg molnupiravir twice daily for 5 days plus usual care or usual care only. A secure, web-based system (Spinnaker) was used for randomisation, which was stratified by age (<50 years vs ≥50 years) and vaccination status (yes vs no). COVID-19 outcomes were tracked via a self-completed online daily diary for 28 days after randomisation. The primary outcome was all-cause hospitalisation or death within 28 days of randomisation, which was analysed using Bayesian models in all eligible participants who were randomly assigned. This trial is registered with ISRCTN, number 30448031.FindingsBetween Dec 8, 2021, and April 27, 2022, 26 411 participants were randomly assigned, 12 821 to molnupiravir plus usual care, 12 962 to usual care alone, and 628 to other treatment groups (which will be reported separately). 12 529 participants from the molnupiravir plus usual care group, and 12 525 from the usual care group were included in the primary analysis population. The mean age of the population was 56·6 years (SD 12·6), and 24 290 (94%) of 25 708 participants had had at least three doses of a SARS-CoV-2 vaccine. Hospitalisations or deaths were recorded in 105 (1%) of 12 529 participants in the molnupiravir plus usual care group versus 98 (1%) of 12 525 in the usual care group (adjusted odds ratio 1·06 [95% Bayesian credible interval 0·81–1·41]; probability of superiority 0·33). There was no evidence of treatment interaction between subgroups. Serious adverse events were recorded for 50 (0·4%) of 12 774 participants in the molnupiravir plus usual care group and for 45 (0·3%) of 12 934 in the usual care group. None of these events were judged to be related to molnupiravir.InterpretationMolnupiravir did not reduce the frequency of COVID-19-associated hospitalisations or death among high-risk vaccinated adults in the community

Pion screening mass at finite chemical potential

Abstract We present a method to compute the responses of meson screening masses to the chemical potential by Taylor expanding the correlator using lattice QCD simulation. We start by comparing the free theory lattice results with the analytical expression. Then, using symmetry arguments, we obtain an expression for the correlator in a series of the chemical potential at finite temperature. Using this, we obtain the lowest order correction to the screening mass at a finite chemical potential for temperatures around 2.5 GeV. Our lattice analysis is limited to isoscalar chemical potential for the pseudoscalar channel. The calculations were performed using (2+1)-flavors of the Highly Improved Staggered Quark (HISQ/tree) action, with the ratio of the strange quark mass to the light quark mass m s /m ℓ = 20 corresponding to pion masses of 160 MeV

Radiation hardened 12T SRAM cell with improved writing capability for space applications

This paper presents an inventive and extremely dependable radiation-hardened by-design (RHBD) 12T SRAM Cell with enhanced writing capability (RHWC-12T) for a space radiation environment. The Proposed RHWC-12T SRAM is designed on Cadence Virtuoso with quad-storage nodes and simulated in 45-nm CMOS technology with the supply voltage of 1.1 V and 27∘C operating temperature. The proposed cell is tolerant to both 0 to 1 and 1 to 0 SEUs (Single event upsets). Also, it provides better speed and stability compared to the other considered SRAM cells such as 6T, 10T Dohar, Quatro, We-Quatro, QUCCE-12T, and NQuatro. According to simulation findings, the proposed SRAM cell provides 1.053× better writing stability than the 10T Dohar SRAM cell. In addition, the write access time improves by 3.56× with 1.36× area overhead than 10T Dohar SRAM cell

Improvement of the “Triangle Method” for Soil Moisture Retrieval Using ECOSTRESS and Sentinel-2: Results over a Heterogeneous Agricultural Field in Northern India

For the purpose of deriving spatiotemporal estimates of soil moisture, the triangle method is one of the most widely used approaches today utilizing remote sensing data. Generally, those techniques are based on the physical relationships that exist when a satellite-derived land surface temperature (Ts) is plotted against a spectral vegetation index (VI). The present study proposes an improvement in the triangle method in retrieving soil moisture over heterogeneous areas. In particular, it proposes a new approach in robustly identifying the extreme points required for the technique’s implementation. Those extreme points are then used in calculating fractional vegetation cover (Fr) and scaled Ts. Furthermore, the study proposes a new approach for calculating the coefficients required to develop the relationships between surface soil moisture (SSM) and Fr/Ts, which is implemented using a model and field data. As a case study, an agricultural field in the Varanasi district in India has been used, on which the triangle method is implemented using ECOSTRESS and Sentinel-2 data. The much-improved spatial resolution satellite data of ~70 m from ECOSTRESS allowed deriving more vivid results of SSM spatial variability for the study area. Comparisons between field soil moisture calculated using the proposed method returned an RMSE of 0.03 and R2 value of 0.84, which are considered very satisfactory. The methodology proposed herein and the results obtained are of significant value with regards to the triangle method, contributing to ongoing efforts at present examining its use for operational product development at a global scale